Metabolic syndrome was strongly associated with left atrial or left atrial appendage thrombus in patients with nonvalvular atrial fibrillation (OR 14.698; P<0.001).
Cross-Sectional (n=294)
Does the addition of metabolic syndrome to standard risk scores improve the prediction of LA/LAA thrombus in patients with nonvalvular atrial fibrillation?
Incorporating metabolic syndrome into standard stroke risk scores significantly improves the prediction of LA/LAA thrombus in patients with nonvalvular atrial fibrillation, especially in those with low traditional risk scores.
Odds Ratio: 14.698
valor p: p=< 0.001
BACKGROUND: Metabolic syndrome (MS) is a risk factor for stroke and thromboembolism event. Left atrial or LA appendage (LA/LAA) thrombus is a surrogate of potential stroke. The relationship between MS and atrial thrombus remains unclear. In this study, we sought to investigate the effect of MS on risk stratification of LA/LAA thrombus formation in patients with nonvalvular atrial fibrillation (NVAF). METHODS: This cross-sectional study enrolled 294 consecutive NVAF patients without prior anticoagulant and lipid-lowering therapies. LA/LAA thrombus was determined by transesophageal echocardiography. Risk assessment of LA/LAA thrombus was performed using the CHADS2 , CHA2DS2 -VASc, MS, CHADS2 -MS, and CHA2DS2 -VASc-MS scores. Logistic regression analyses were performed to determine which factors were significantly related to LA/LAA thrombus. Odds ratio (OR) including 95% confidence interval was also calculated. The predictive powers of different scores for the risk of LA/LAA thrombus were represented by C-statistics and compared by receiver operating characteristic (ROC) analysis. RESULTS: LA/LAA thrombi were identified in 56 patients (19.0%). Logistic analysis showed that MS was the strongest risk factor for LA/LAA thrombus in NVAF patients (OR = 14.698, P < 0.001). ROC curve analyses revealed that the C-statistics of CHADS2 -MS and CHA2DS2 -VASc-MS was significantly higher than those of CHADS2 and CHA2DS2 -VASc scores (CHADS2 -MS vs. CHADS2 , 0.807 vs. 0.726, P = 0.0019). Furthermore, MS was helpful for identifying individuals with a high risk of LA/LAA thrombus in the population with a low risk of stroke (CHADS2 or CHA2DS2 -VASc score = 0). CONCLUSIONS: MS is associated with LA/LAA thrombus risk in patients with NVAF. In addition to the CHADS2 and CHA2DS2 -VASc scores, the CHADS2 -MS and CHA2DS2 -VASc-MS scores provide additional information on stroke risk assessment.
Chen et al. (Mon,) conducted a cross-sectional in Nonvalvular atrial fibrillation (NVAF) (n=294). Metabolic syndrome vs. No metabolic syndrome was evaluated on Left atrial or left atrial appendage (LA/LAA) thrombus (OR 14.698, p=< 0.001). Metabolic syndrome was strongly associated with left atrial or left atrial appendage thrombus in patients with nonvalvular atrial fibrillation (OR 14.698; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: